Zhongsheng Pharmaceutical announced that the holding subsidiary Zhongsheng Ruichuang has received a patent certificate issued by the Japan Patent Office. The patent name is “Preparation and Use of Polypeptides”. The patent number is 7672503. The patent application date is May 30, 2022. The patentee is Zhongsheng Ruichuang, and the patent period is 20 years from the date of application. This patent is a compound patent for the RAY1225 project and is the core patent of this project. RAY1225 injection is a polypeptide drug with dual agonist activity of GLP-1 receptor and GIP receptor. It is currently in phase III clinical trials. This patent authorization will help the company to further improve the intellectual property protection system and give full play to the advantages of independent intellectual property rights, but it will not have a significant impact on the company's short-term financial situation and business performance.

Zhongsheng Pharmaceutical announced that the holding subsidiary Zhongsheng Ruichuang has received a patent certificate issued by the Japan Patent Office. The patent name is “Preparation and Use of Polypeptides”. The patent number is 7672503. The patent application date is May 30, 2022. The patentee is Zhongsheng Ruichuang, and the patent period is 20 years from the date of application. This patent is a compound patent for the RAY1225 project and is the core patent of this project. RAY1225 injection is a polypeptide drug with dual agonist activity of GLP-1 receptor and GIP receptor. It is currently in phase III clinical trials. This patent authorization will help the company to further improve the intellectual property protection system and give full play to the advantages of independent intellectual property rights, but it will not have a significant impact on the company's short-term financial situation and business performance.